Open AccessResults of Lucentis use as a routine practice in wet age-related macular degeneration patients
Author(s) -
И. А. Лоскутов,
Лоскутов Игорь Анатольевич
Publication year - 2014
Publication title -
oftalʹmologičeskie vedomosti
Language(s) - English
Resource type - Journals
eISSN - 2412-5423
pISSN - 1998-7102
DOI - 10.17816/ov2014147-57
Subject(s) - ranibizumab , medicine , visual acuity , quality of life (healthcare) , macular degeneration , ophthalmology , clinical practice , optometry , physical therapy , surgery , chemotherapy , nursing , bevacizumab
Ranibizumab treatment leads to rapid visual acuity improvement, which may be observed in as little as a week after the first injection, and may lead to quality of life improvement as estimated by VFQ-25 questionnaire. The retinal thickness progressively decreased in the course of treatment, what along with the lesion size reduction results in visual function improvement. The quality of life assessment using the VFQ-25 questionnaire revealed an improvement in all subscale positions during first months of monitoring, when visual acuity increase helps the patient perform routine daily activities. The longer Lucentis is needed and used, the trend is less optimistic, and patients acknowledge a quality of life decrease. Total VFQ-25 score has well-defined rises and descents, favoring treatment efficacy as well as the necessity of additional injections according to clinical need.